130319 Edanz Gunma 3

465 views
363 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
465
On SlideShare
0
From Embeds
0
Number of Embeds
33
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

130319 Edanz Gunma 3

  1. 1. Reading strategies:Flow, figures, graphs and tables Gunma University 19 March 2013 Jeff Robens, PhD Senior Editor
  2. 2. Today’s presentation … Flow of ideas in a manuscript Preparing and reading figures Preparing and reading graphs and tables
  3. 3. Flow of ideas Manuscript flow Background and context Knowledge gaps Introduction Objectives Methods Methods Results and figures Results Summary of findings Relevance of findings Discussion Implications for the field
  4. 4. Flow of ideas Advanced reading strategies Read Title and Abstract first During your literature search Read last paragraph of Introduction for hypothesis/objectives Read Figures Refer to Results and Methods for specific information Read Discussion for conclusions and implications
  5. 5. Display Items Present large amount Usually the first thing of data quickly and readers will look at efficiently Figures, graphs & tables Use separate Stand alone subpanels to figure legends organize data
  6. 6. Display Items What’s wrong with this figure? Unclear labels Poorly drawn indicatorsUnclear figure legend Figure 1 AHLE demonstrating distorted brachial artery and classical vessel proliferation. Kukreja et al. BMJ Case Rep. 2011;doi:10.1136/bcr.02.2011.3836.
  7. 7. Display Items Well-designed Figures Clear labeling Scale bars(g) Liver tissue from mice withPDGF-BB or vector tumors werestained with H&E or triple stainedwith Ter119, Ki67 and DAPI. Arrowsand dashed circles indicatedhematopoietic foci. Indicators Xue et al. Nat Med. 2012;18:100–110.
  8. 8. Display Items Figure legends Methods Indicators Results Statistics(a) One hundred ten lung cancer tissues were analyzed for miR-103, miR-222, miR-203 and miR-30c expression byISH and then for MET by IHC. The top row shows the miR-103 signal (blue), the MET signal (red) and the mixedsignal, in which fluorescent yellow indicates miRNA and protein co-expression; there is a lack of miR-103 in thepresence of MET expression. In the serial section of the same cancer (in the second row), miR-222, the MET imageand the co-expression of miR-222 and MET are shown. Many cancer cells positive for miR-222 also express MET(yellow). The arrows in the left panel (in the third row) point to benign stromal cells that express miR-203 (blue)and not MET. The other images in the third row show the MET signal (red) and the mixed signal. The arrow in theleft image in the fourth row points to cancer cells positive for miR-30c. The right images in each row show the RGBimage of the ISH or IHC reaction. (b) Box plots showing miRNA expression in 40 individuals with lung cancer. Real-time PCR was used to classify tumors into two groups, EGFR-MET low and EGFR-MET high, using a round functionwith a cutoff of 0.5 (2(−ΔCt)). *P < 0.0001 by Students t test. (c) XY scatter plots showing inverse correlationbetween MET and miR-103 and MET and miR-203. (d) MET and EGFR IHC on 40 lung tumor tissues. Onerepresentative case from 17 metastatic tumors expressing both MET and EGFR is shown. The large green arrowspoint to the tumor cells, and the small black arrows point to the stroma. Scale bars, 100 μm. Garofalo et al. Nat Med. 2012;18:74–82.
  9. 9. Display Items Figure Exercises Finding information from 2 different figures Matching figure legends to figures
  10. 10. Display Items Figure Exercises Immunohistochemistry of N-cadherin expression in papillary RCC. Papillary RCC type II with high nuclear polymorphism and abundant cytoplasm on the tumor cells (A, x20) displays membranous expression of N-cadherin (B, x40). Papillary RCC type I with single layer of cuboidal cells and a small cytoplasmic rim (C, x20) shows only a weak cytoplasmic N-cadherin (D, x40). Does papillary RCC type I or type II have higher expression of N-cadherin? Where does N-cadherin localize in these two types of papillary RCC? Ludwig et al. (2012). Diagnostic Pathol. 7:95.
  11. 11. Display Items Figure Exercises Immunohistochemistry of N-cadherin expression in papillary RCC. Papillary RCC type II with high nuclear polymorphism and abundant cytoplasm on the tumor cells (A, x20) displays membranous expression of N-cadherin (B, x40). Papillary RCC type I with single layer of cuboidal cells and a small cytoplasmic rim (C, x20) shows only a weak cytoplasmic N-cadherin (D, x40). Does papillary RCC type I or type II have higher expression of N-cadherin? Ludwig et al. (2012). Diagnostic Pathol. 7:95.
  12. 12. Display Items Figure Exercises Immunohistochemistry of N-cadherin expression in papillary RCC. Papillary RCC type II with high nuclear polymorphism and abundant cytoplasm on the tumor cells (A, x20) displays membranous expression of N-cadherin (B, x40). Papillary RCC type I with single layer of cuboidal cells and a small cytoplasmic rim (C, x20) shows only a weak cytoplasmic N-cadherin (D, x40). Does papillary RCC type I or type II have higher expression of N-cadherin? Papillary RCC type II Ludwig et al. (2012). Diagnostic Pathol. 7:95.
  13. 13. Display Items Figure Exercises Immunohistochemistry of N-cadherin expression in papillary RCC. Papillary RCC type II with high nuclear polymorphism and abundant cytoplasm on the tumor cells (A, x20) displays membranous expression of N-cadherin (B, x40). Papillary RCC type I with single layer of cuboidal cells and a small cytoplasmic rim (C, x20) shows only a weak cytoplasmic N-cadherin (D, x40). Where does N-cadherin localize in these two types of papillary RCC? Ludwig et al. (2012). Diagnostic Pathol. 7:95.
  14. 14. Display Items Figure Exercises Immunohistochemistry of N-cadherin expression in papillary RCC. Papillary RCC type II with high nuclear polymorphism and abundant cytoplasm on the tumor cells (A, x20) displays membranous expression of N-cadherin (B, x40). Papillary RCC type I with single layer of cuboidal cells and a small cytoplasmic rim (C, x20) shows only a weak cytoplasmic N-cadherin (D, x40). Where does N-cadherin localize in these two types of papillary RCC? Type II: membrane Type I: cytoplasm Ludwig et al. (2012). Diagnostic Pathol. 7:95.
  15. 15. Display Items Figure Exercises Effects of sorafenib on phospho-ERK1/2, VEGF expression, angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with vehicle or 40 mg kg−1 per day sorafenib for 21 days. Representative pictures of blood vessels stained with anti-CD31, proliferative cells stained with anti-Ki-67, apoptotic cells stained with anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2 stained with anti-phospho-ERK antibodies in vehicle- and drug-treated tumours are shown ( × 200). Experiments were repeated twice with similar results. Does sorafenib increase cell proliferation (growth) or cell death (apoptosis)? Based on this data, do you think p-ERK is correlated with cell proliferation or cell death? Yuen et al. (2011). Brit J Cancer 104:941—947.
  16. 16. Display Items Figure Exercises Effects of sorafenib on phospho-ERK1/2, VEGF expression, angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with vehicle or 40 mg kg−1 per day sorafenib for 21 days. Representative pictures of blood vessels stained with anti-CD31, proliferative cells stained with anti-Ki-67, apoptotic cells stained with anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2 stained with anti-phospho-ERK antibodies in vehicle- and drug-treated tumours are shown ( × 200). Experiments were repeated twice with similar results. Does sorafenib increase cell proliferation (growth) or cell death (apoptosis)? Yuen et al. (2011). Brit J Cancer 104:941—947.
  17. 17. Display Items Figure Exercises Effects of sorafenib on phospho-ERK1/2, VEGF expression, angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with vehicle or 40 mg kg−1 per day sorafenib for 21 days. Representative pictures of blood vessels stained with anti-CD31, proliferative cells stained with anti-Ki-67, apoptotic cells stained with anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2 stained with anti-phospho-ERK antibodies in vehicle- and drug-treated tumours are shown ( × 200). Experiments were repeated twice with similar results. Does sorafenib increase cell proliferation (growth) or cell death (apoptosis)? Sorafenib increases apoptosis Yuen et al. (2011). Brit J Cancer 104:941—947.
  18. 18. Display Items Figure Exercises Effects of sorafenib on phospho-ERK1/2, VEGF expression, angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with vehicle or 40 mg kg−1 per day sorafenib for 21 days. Representative pictures of blood vessels stained with anti-CD31, proliferative cells stained with anti-Ki-67, apoptotic cells stained with anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2 stained with anti-phospho-ERK antibodies in vehicle- and drug-treated tumours are shown ( × 200). Experiments were repeated twice with similar results. Based on this data, do you think p-ERK is correlated with cell proliferation or cell death? Yuen et al. (2011). Brit J Cancer 104:941—947.
  19. 19. Display Items Figure Exercises Effects of sorafenib on phospho-ERK1/2, VEGF expression, angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with vehicle or 40 mg kg−1 per day sorafenib for 21 days. Representative pictures of blood vessels stained with anti-CD31, proliferative cells stained with anti-Ki-67, apoptotic cells stained with anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2 stained with anti-phospho-ERK antibodies in vehicle- and drug-treated tumours are shown ( × 200). Experiments were repeated twice with similar results. Based on this data, do you think p-ERK is correlated with cell proliferation or cell death? Yuen et al. (2011). Brit J Cancer 104:941—947.
  20. 20. Display Items Figure Exercises Effects of sorafenib on phospho-ERK1/2, VEGF expression, angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with vehicle or 40 mg kg−1 per day sorafenib for 21 days. Representative pictures of blood vessels stained with anti-CD31, proliferative cells stained with anti-Ki-67, apoptotic cells stained with anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2 stained with anti-phospho-ERK antibodies in vehicle- and drug-treated tumours are shown ( × 200). Experiments were repeated twice with similar results. Based on this data, do you think p-ERK is correlated with cell proliferation or cell death? Yuen et al. (2011). Brit J Cancer 104:941—947.
  21. 21. Display Items Figure Exercises Effects of sorafenib on phospho-ERK1/2, VEGF expression, angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with vehicle or 40 mg kg−1 per day sorafenib for 21 days. Representative pictures of blood vessels stained Decrease with anti-CD31, proliferative cells stained with anti-Ki-67, apoptotic cells stained with anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2 stained with anti-phospho-ERK antibodies in vehicle- and drug-treated tumours are shown ( × 200). Experiments Increase were repeated twice with similar results. Based on this data, do you think p-ERK is correlated with cell proliferation or cell death? Decrease p-ERK is correlated with cell proliferation Yuen et al. (2011). Brit J Cancer 104:941—947.
  22. 22. Display Items Figure ExercisesA B C Yuen et al. (2011). Brit J Cancer 104:941—947.
  23. 23. Display Items Figure ExercisesImages demonstrating clear metastatic lesions in the lungs of arthritic PyV MT mice. A-F: Representative imagesof lungs showing metastatic lesions. A-C:C57/BL6 mice, C57/BL6+CII at 9 and 18 wks (no metastatic lesions) D: PyVMT mice(no metastatic lesions); E and F: PyV MT+ CII at 9 and 18 wks respectively (arrows represent lung lesions);G-L: H&E of the lung sections: The arrows represent metastatic lesions in PyV MT + CII at 9 and 18 wks (K and L)versus no lesions in control C57/BL6, C57/BL6 + CII at 9 or 18 wks and PyV MT lung (G - J). N = 10-13 mice fromeach group were examined with similar results. The images of the H&E sections were taken at 400× magnification.Increased cellular infiltration within the PyV MT tumors of arthritic versus non-arthritic mice. A - F: H&E stainingshowing inflammation in the tumor microenvironment; A and D: PyV MT (Low inflammation); B and E: PyV MT +CII at 9 (severe inflammation); C and F: PyV MT + CII at 18 wks (severe inflammation). The images of tumorsections were taken at 200× (A-C) and 400× (D-F) magnification from the same area. Representative of n = 10 miceis shown. G-L: Increased macrophage infiltration within the PyV MT tumors of arthritic versus non-arthritic miceindicated by F4/80 staining. The images of the macrophage staining were taken at 600× magnification.Representative of n = 3 mice is shown.Increased infiltration of neutrophils in the bones and lungs of arthritic PyV MT mice. A-F: Naphthol AS-Dchloroacetate esterase staining of the bones and lungs for neutrophils. Increased infiltration of neutrophils inbones (A-C) and lungs (D-F) of arthritic PyV MT mice indicated by arrows. Representative of 10 fields in n = 10mice is shown. The images of the bones and lungs were taken at 400× and 200× magnification respectively. Yuen et al. (2011). Brit J Cancer 104:941—947.
  24. 24. Display Items Figure ExercisesImages demonstrating clear metastatic lesions in the lungs of arthritic PyV MT mice. A-F: Representative imagesof lungs showing metastatic lesions. A-C:C57/BL6 mice, C57/BL6+CII at 9 and 18 wks (no metastatic lesions) D: PyVMT mice(no metastatic lesions); E and F: PyV MT+ CII at 9 and 18 wks respectively (arrows represent lung lesions);G-L: H&E of the lung sections: The arrows represent metastatic lesions in PyV MT + CII at 9 and 18 wks (K and L)versus no lesions in control C57/BL6, C57/BL6 + CII at 9 or 18 wks and PyV MT lung (G - J). N = 10-13 mice fromeach group were examined with similar results. The images of the H&E sections were taken at 400× magnification.Increased cellular infiltration within the PyV MT tumors of arthritic versus non-arthritic mice. A - F: H&E stainingshowing inflammation in the tumor microenvironment; A and D: PyV MT (Low inflammation); B and E: PyV MT +CII at 9 (severe inflammation); C and F: PyV MT + CII at 18 wks (severe inflammation). The images of tumorsections were taken at 200× (A-C) and 400× (D-F) magnification from the same area. Representative of n = 10 miceis shown. G-L: Increased macrophage infiltration within the PyV MT tumors of arthritic versus non-arthritic miceindicated by F4/80 staining. The images of the macrophage staining were taken at 600× magnification.Representative of n = 3 mice is shown.Increased infiltration of neutrophils in the bones and lungs of arthritic PyV MT mice. A-F: Naphthol AS-Dchloroacetate esterase staining of the bones and lungs for neutrophils. Increased infiltration of neutrophils inbones (A-C) and lungs (D-F) of arthritic PyV MT mice indicated by arrows. Representative of 10 fields in n = 10mice is shown. The images of the bones and lungs were taken at 400× and 200× magnification respectively. Yuen et al. (2011). Brit J Cancer 104:941—947.
  25. 25. Display Items Figure ExercisesA B C Yuen et al. (2011). Brit J Cancer 104:941—947.
  26. 26. Display Items Figure ExercisesImages demonstrating clear metastatic lesions in the lungs of arthritic PyV MT mice. A-F: Representative imagesof lungs showing metastatic lesions. A-C:C57/BL6 mice, C57/BL6+CII at 9 and 18 wks (no metastatic lesions) D: PyVMT mice(no metastatic lesions); E and F: PyV MT+ CII at 9 and 18 wks respectively (arrows represent lung lesions);G-L: H&E of the lung sections: The arrows represent metastatic lesions in PyV MT + CII at 9 and 18 wks (K and L)versus no lesions in control C57/BL6, C57/BL6 + CII at 9 or 18 wks and PyV MT lung (G - J). N = 10-13 mice fromeach group were examined with similar results. The images of the H&E sections were taken at 400× magnification.Increased cellular infiltration within the PyV MT tumors of arthritic versus non-arthritic mice. A - F: H&E stainingshowing inflammation in the tumor microenvironment; A and D: PyV MT (Low inflammation); B and E: PyV MT +CII at 9 (severe inflammation); C and F: PyV MT + CII at 18 wks (severe inflammation). The images of tumorsections were taken at 200× (A-C) and 400× (D-F) magnification from the same area. Representative of n = 10 miceis shown. G-L: Increased macrophage infiltration within the PyV MT tumors of arthritic versus non-arthritic miceindicated by F4/80 staining. The images of the macrophage staining were taken at 600× magnification.Representative of n = 3 mice is shown.Increased infiltration of neutrophils in the bones and lungs of arthritic PyV MT mice. A-F: Naphthol AS-Dchloroacetate esterase staining of the bones and lungs for neutrophils. Increased infiltration of neutrophils inbones (A-C) and lungs (D-F) of arthritic PyV MT mice indicated by arrows. Representative of 10 fields in n = 10mice is shown. The images of the bones and lungs were taken at 400× and 200× magnification respectively. Yuen et al. (2011). Brit J Cancer 104:941—947.
  27. 27. Display Items Figure ExercisesA B C Yuen et al. (2011). Brit J Cancer 104:941—947.
  28. 28. Display Items Figure ExercisesImages demonstrating clear metastatic lesions in the lungs of arthritic PyV MT mice. A-F: Representative imagesof lungs showing metastatic lesions. A-C:C57/BL6 mice, C57/BL6+CII at 9 and 18 wks (no metastatic lesions) D: PyVMT mice(no metastatic lesions); E and F: PyV MT+ CII at 9 and 18 wks respectively (arrows represent lung lesions);G-L: H&E of the lung sections: The arrows represent metastatic lesions in PyV MT + CII at 9 and 18 wks (K and L)versus no lesions in control C57/BL6, C57/BL6 + CII at 9 or 18 wks and PyV MT lung (G - J). N = 10-13 mice fromeach group were examined with similar results. The images of the H&E sections were taken at 400× magnification.Increased cellular infiltration within the PyV MT tumors of arthritic versus non-arthritic mice. A - F: H&E stainingshowing inflammation in the tumor microenvironment; A and D: PyV MT (Low inflammation); B and E: PyV MT +CII at 9 (severe inflammation); C and F: PyV MT + CII at 18 wks (severe inflammation). The images of tumorsections were taken at 200× (A-C) and 400× (D-F) magnification from the same area. Representative of n = 10 miceis shown. G-L: Increased macrophage infiltration within the PyV MT tumors of arthritic versus non-arthritic miceindicated by F4/80 staining. The images of the macrophage staining were taken at 600× magnification.Representative of n = 3 mice is shown.Increased infiltration of neutrophils in the bones and lungs of arthritic PyV MT mice. A-F: Naphthol AS-Dchloroacetate esterase staining of the bones and lungs for neutrophils. Increased infiltration of neutrophils inbones (A-C) and lungs (D-F) of arthritic PyV MT mice indicated by arrows. Representative of 10 fields in n = 10mice is shown. The images of the bones and lungs were taken at 400× and 200× magnification respectively. Yuen et al. (2011). Brit J Cancer 104:941—947.
  29. 29. Display Items Figure ExercisesA B C Yuen et al. (2011). Brit J Cancer 104:941—947.
  30. 30. Display Items Is this a good table? Alignment and formatting problems Alignment of Alignment of Alignment of text parentheses decimals Data Lines Shading similarity Tumor size Tumor size % Treatment (mm 3) before (mm3) after decrease time treatment treatment Mean (±SD) Mean (±SD) Group 1 423.2 (6.23) 232.8 (3.18) 44.99 4 months Group 2 286.43 (4.8) 157.32 (2.29) 45.08 14 weeks Group 3 342.7 (6.88) 218.4 (5.2) 36.27 3.5 months Group 4 404 (3) 302 (4.21) 25.247 90 days
  31. 31. Display Items Making a good table Tumor size Tumor size % Treatment (mm 3) before (mm3) after decrease time treatment treatment Mean (±SD) Mean (±SD) Group 1 423.2 (6.23) 232.8 (3.18) 44.99 4 months Group 2 286.43 (4.8) 157.32 (2.29) 45.08 14 weeks Group 3 342.7 (6.88) 218.4 (5.2) 36.27 3.5 months Group 4 404 (3) 302 (4.21) 25.247 90 days Tumor size Tumor size % Treatment (mm3) before (mm3) after decrease time treatment treatment (weeks) Mean (±SD) Mean (±SD) Group 1 423.20 (6.23) 232.80 (3.18) 44.99 16 Group 2 286.43 (4.80) 157.32 (2.29) 45.08 14 Group 3 342.70 (6.88) 218.40 (5.20) 36.27 14 Group 4 404.00 (3.00) 302.00 (4.21) 25.25 12
  32. 32. Display Items A good tableClear and concise table captionData aligned and Abbreviations formatted defined Muñoz et al. New Engl J Med. 2003;348:518−527.
  33. 33. Display Items Table exercises Find specific information (5) from table
  34. 34. Display Items Table exercises Dementia from Alzheimer Disease and Mixed Pathologies in the Oldest Old James et al. (2012). JAMA 307:1798—1800.
  35. 35. Display Items Table exercises Dementia from Alzheimer Disease and Which age group had a higher the Oldest Old women? Mixed Pathologies in percentage of ≥ 90 James et al. (2012). JAMA 307:1798—1800.
  36. 36. Display Items Table exercises Dementia from Alzheimer Disease and Which statistical tests were usedthecalculate significance? Mixed Pathologies in to Oldest Old Χ2 or t test James et al. (2012). JAMA 307:1798—1800.
  37. 37. Display Items Table exercises Dementia from Alzheimer Disease and How many participants over 90 y were diagnosed with Mixed Pathologies in the Oldest Old dementia? 161 participants James et al. (2012). JAMA 307:1798—1800.
  38. 38. Display Items Table exercises Dementia from Alzheimer Disease and Of those with dementia, how many did not have pathological Pathologies in the Oldest Old Mixed diagnosis of AD in each age group? 12.6% of 65−89 & 13% of ≥ 90 James et al. (2012). JAMA 307:1798—1800.
  39. 39. Display Items Table exercises Dementia from Alzheimer Disease and Was the presence of neocortical Lewy bodies statistically significant between the the Oldest Old Mixed Pathologies in two age groups? No James et al. (2012). JAMA 307:1798—1800.
  40. 40. Display Items Graph types Bar graphs Compares a single variable among groups Line graphs Shows a series of data over time, shows trends Scatter plots Shows correlation between variables Box plots Compare distribution of data among groups
  41. 41. Display Items Bar graphs CXCR5+ T helper cells mediate protective immunity against tuberculosis Statistical significance Measured variable GroupsFigure 7 Adoptive transfer of B6 but not Cxcr5-/- CD4+ T cells rescues T cell localization and protection inCxcr5-/-Mtb-infected mice... (B) The average size of B cell lymphoid follicles in FFPE lung sections on day50 using the morphometric tool of the Zeiss Axioplan microscope… *** P = 0.0005. Slight et al. J Clin Invest. 2013;doi:10.1172/JCI65728.
  42. 42. Display Items Error bars CXCR5+ T helper cells mediate protective immunity against tuberculosis Error bars maySD = variability in the data represent standardSEM = accuracy of the deviation (SD) or theestimated mean standard error of the mean (SEM).SEM = SD/√sample sizeSEM is always smaller thanthe SD Figure 7 Adoptive transfer of B6 but not Cxcr5-/- CD4+ T cells rescues T cell localization and protection in Cxcr5-/-Mtb-infected mice... The data points represent the mean (SD) of values from 4–6 mice. Slight et al. J Clin Invest. 2013;doi:10.1172/JCI65728.
  43. 43. Display Items Line graphs - Trends GroupsMeasured variable Time Figure 2 Improvement of B-cell function by Stem Cell Educator therapy. (A) Fasting C-peptide levels of T1D participants over 24 weeks… Zhao et al. BMC Med. 2012;10:3.
  44. 44. Display Items Scatter plots - Correlation r = correlation coefficient R2 = coefficient of determination Variable 1 Trend line Variable 2Figure 3 Expression of query and non-query genes in uniform and disturbed flow pattern regions of rataorta... (d) Correlation between ZFP36 and TNF mRNA expression (n = 26)… Maleki et al. J Mol Med. 2013;91:129−139.
  45. 45. Display Items Box plots - Distributions Maximum 75% Median 25% MinimumFigure 2 Dual luciferase reporter assays. The ratios of Firefly luciferase activity (signal S) to Renillaluciferase (control C) are displayed using box and whisker plots… Hijikata et al. Hum Genetics. 2012;131:675−682.
  46. 46. Display Items Graph exercises Scanning graphs for information Which type of graph for which type of data set?
  47. 47. Display Items Graph exercises By how much did the phagocytic index decrease in both conditions by the addition of the CRT-blocking peptide? Normal Decreased MDS Decreased ~45 to ~35 by ~10 ~82 to ~12 by ~70
  48. 48. Display Items Graph exercises At what age did the numbers of deaths decrease in the time period from 1959−1965 in men? 75−79
  49. 49. Display Items Graph exercises Which age(s) and time period(s) did the number of deaths from lung cancer increase to more than 10% for female and male smokers? Women Men Men 2000−2010, 80−84 1982−1988, 75−79 2000−2010, 75−79
  50. 50. Display Items Graph exercises The effect of a drug on Bar graph cortisol levels over time Comparing the distribution of cortisol levels in control Scatter plot vs. drug-treated groups Comparing the mean level of cortisol levels in control Line graph vs. drug-treated groups Determining the relationship between drug concentration Box plot and cortisol levels
  51. 51. Any questions? Thank you! edanzediting.co.jp/gunma2013 Download and further reading @JournalAdvisor Follow us on Twitter facebook.com/JournalAdvisor Like us on Facebookwww.edanzediting.co.jp

×